Therapeutic safety and effects of cytokine induced killer cells activated by retronectin for advanced cancer patients

Chinese Journal of Clinical Oncology

Volumn 36, Issue 20, 2009, Pages 1163-1166

  Wang, Shiyong ^a   Zhang, Hui ^a   Du, Weili ^a   Zhang, Yuan ^a   Wulan, Tuya ^a   He, Ying ^a   Liu, Sa ^a   Zhang, Zhe ^a   Wang, Jialing ^a   Wu, Xiuyan ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Adoptive cellular immunotherapy; Cytokine induced killer cells (CIK); Malignant tumor; Quality of life

Indexed keywords

CYTOKINE; DOCETAXEL; REAGENT; RETRONECTIN; UNCLASSIFIED DRUG;

ADVANCED CANCER; APPETITE; ARTICLE; BLOOD AUTOTRANSFUSION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CELL ACTIVATION; CELLULAR IMMUNITY; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; DEPRESSION; DISEASE SEVERITY; EUPHORIA; FEVER; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGY; INSOMNIA; KILLER CELL; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; MENTAL PERFORMANCE; OVERALL SURVIVAL; PALLIATIVE THERAPY; PHYSICAL ACTIVITY; QUALITY OF LIFE; SAFETY; THERAPY EFFECT; TRANSFUSION;

EID: 77951560991     PISSN: 16727118     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1000-8179.2009.20.007     Document Type: Article

References (10)

1. Blattman JN, Greenberg PD. Cancer immunotherapy: a treatment for the masses[J]. Science, 2004, 305(5681): 200-205.
2. Introna M, Franceschetti M, Ciocca A, et al. Rapid and massive expansion of cord blood- derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia replase after cord blood transplantation[J]. Bone Marrow Transplant, 2006, 38 (9): 621-627. (Pubitemid 44596854)
3. Duffaud F, Therasse P. New guidelines to evaluate the response to treatment in solid tumors[J]. Bull Cancer, 2000, 87(12): 881-886. (Pubitemid 32094649)
4. Nishimura R, Baker J, Beilhack A, et al. In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity[J]. Blood, 2008, 112 (6): 2563-2574.